Baricitinib for Cutaneous Dermatomyositis

Status Withdrawn

Clinical Trial Summary

This is a phase 2, single-center study in patients with active cutaneous DM who have had an inadequate response. An inadequate response is defined as no improvement with standard of care treatment based on the investigator's opinion. All subjects will initially receive baricitinib 2mg daily for 8 weeks. If no unexpected serious adverse events related to baricitinib have occurred during the first 8 weeks of treatment in the opinion of the investigator, the dose will be increased to 4 mg daily for 16 weeks. Visits are scheduled at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, and 24 weeks. Evaluation of primary endpoint occurs at week 24. All subjects receive a phone call from study

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Dermatomyositis

Clinical Trial Details

NCT number	NCT05361109
Study type	Interventional
Source	University of Washington
Contact
Status	Withdrawn
Phase	Phase 2
Start date	June 1, 2022
Completion date	March 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05833711` - Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy	Phase 2
Not yet recruiting	`NCT06284954` - A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis	Phase 2
Completed	`NCT01906372` - Acthar in Treatment of Refractory Dermatomyositis and Polymyositis	Phase 2
Completed	`NCT01813617` - Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis	N/A
Completed	`NCT01165008` - Anakinra in Myositis	Phase 2/Phase 3
Completed	`NCT00004357` - Absorption of Corticosteroids in Children With Juvenile Dermatomyositis	Phase 2
Recruiting	`NCT05832034` - Add-on Intravenous Immunoglobulins in Early Myositis	Phase 2
Recruiting	`NCT05979441` - A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy	Phase 3
Not yet recruiting	`NCT05027152` - Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties	N/A
Active, not recruiting	`NCT04723303` - Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)	Early Phase 1
Completed	`NCT03267277` - Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis	Phase 2/Phase 3
Recruiting	`NCT05437263` - A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis	Phase 3
Active, not recruiting	`NCT04044690` - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)	Phase 3
Recruiting	`NCT05523167` - A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.	Phase 2/Phase 3
Not yet recruiting	`NCT06004817` - Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis
Recruiting	`NCT03324152` - Effects of High-intensity Interval Training (HIIT) in Recent Onset Polymyositis and Dermatomyositis	N/A
Completed	`NCT02043548` - Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis	Phase 2
Completed	`NCT03414086` - Predictor of Clinical Response to Acthar in Myositis
Completed	`NCT04628936` - Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.	Phase 2
Recruiting	`NCT03293615` - Exercise Capacity of Patients With Dermatomyosis	N/A